Is the official narrative surrounding the latest Ebola outbreak withholding critical information? We examine discrepancies and question...
Pharmaceuticals
Reports of emotional blunting with popular GLP-1 drugs raise unsettling questions. Is this a mere side effect,...
Are tariffs on pharmaceuticals a smokescreen for something far more insidious? Whispers suggest a global consortium is...
A major study claims statin side effects are largely psychological, but inconsistencies in data access and funding...
New drug discount site TrumpRx promises lower prices, but investigative analysts suggest the platform's backend may be...
An investigative look into the sudden breakthrough in pancreatic cancer research and the unanswered questions surrounding its...
An investigation into the strange financial discrepancies and bold future promises of biotech leader Alnylam during a...
A deep dive into the logistical shift behind Amazon Pharmacy's new distribution of Wegovy and the unanswered...
A deep dive into the unexplained statistical anomalies and pharmaceutical timing surrounding the current winter respiratory crisis.
New investigations reveal that modern flu medications might be acting as biological transceivers for a subterranean thermal...
New evidence suggests the recently approved weight loss pill serves as a biological conduit for a massive...
The FDA's expanded approval of Addyi for older women raises subtle questions about its true, unadvertised effects...
Hundreds of thousands affected by the Atorvastatin recall. Is it merely FDA oversight, or a more intricate...
Eli Lilly's massive Alabama investment sparks questions. Is this facility more than just a drug plant? We...
The US and UK announced a zero-tariff deal on pharmaceuticals, but what lies beneath this sudden agreement?...
Did a promising Alzheimer's drug just hit a dead end, or is this merely a strategic detour...
Novo Nordisk's groundbreaking Alzheimer's drug trial has hit a wall. But is it a simple failure, or...
Novo Nordisk's CEO is undeterred after a major acquisition loss. But who is really pulling the strings...
A weight-loss drug sweeping Russia raises alarming questions about its origins and widespread use.
